Lung cancer gene therapy trial halted early

NCT ID NCT05062980

Terminated Disease control Sponsor: Genprex, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 07, 2026 · Last updated Jun 17, 2026 · Updated 1 time

Summary

This early-stage trial tested a new gene therapy (quaratusugene ozeplasmid) combined with an immunotherapy drug (pembrolizumab) for people with advanced non-small cell lung cancer who had already been treated. The goal was to see if the combination was safe and worked better than standard chemotherapy. However, the study was stopped early because not enough people signed up, so only 5 participants were enrolled.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Mary Crowley Cancer Research

Dallas, Texas, 75230, United States
Millennium Oncology

Houston, Texas, 77090, United States
Moffitt Cancer Center - Magnolia Campus

Tampa, Florida, 33612, United States
Ochsner Clinic Foundation

New Orleans, Louisiana, 70121, United States
The Valley Hospital - Luckow Pavilion

Paramus, New Jersey, 07652, United States
Washington University School of Medicine - Siteman Cancer Center

St Louis, Missouri, 63110, United States

Conditions

Explore the condition pages connected to this study.

NON SMALL CELL LUNG CANCER